| __timestamp | Exelixis, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 13673000 |
| Thursday, January 1, 2015 | 96351000 | 14358000 |
| Friday, January 1, 2016 | 95967000 | 12203000 |
| Sunday, January 1, 2017 | 112171000 | 18125000 |
| Monday, January 1, 2018 | 182257000 | 17071000 |
| Tuesday, January 1, 2019 | 336964000 | 20018000 |
| Wednesday, January 1, 2020 | 547851000 | 32788000 |
| Friday, January 1, 2021 | 693716000 | 44966000 |
| Saturday, January 1, 2022 | 891813000 | 311681000 |
| Sunday, January 1, 2023 | 1044071000 | 77707000 |
| Monday, January 1, 2024 | 910408000 |
Unlocking the unknown
In the competitive landscape of biotechnology and pharmaceuticals, strategic investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, Exelixis, Inc. has demonstrated a robust commitment to R&D, with spending increasing by over 450% from 2014 to 2023. This strategic focus has positioned Exelixis as a leader in the field, with R&D expenses peaking at over $1 billion in 2023.
In contrast, Lantheus Holdings, Inc. has maintained a more conservative approach, with R&D spending growing by approximately 470% over the same period. Despite this, Lantheus made a significant leap in 2022, with a notable increase in R&D expenses, reflecting a strategic pivot towards innovation.
These trends underscore the importance of R&D in driving competitive advantage and highlight the differing strategies of these two industry players.
Eli Lilly and Company vs Lantheus Holdings, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Novartis AG and Exelixis, Inc. Allocate Funds
Comparing Innovation Spending: Amgen Inc. and Exelixis, Inc.
Research and Development: Comparing Key Metrics for Sanofi and Lantheus Holdings, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Blueprint Medicines Corporation or Lantheus Holdings, Inc.: Who Invests More in Innovation?